A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
Active, not recruiting · NCT05815485 · Registry updated 2025-03-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia | COVID-19, Coronaviridae Infections, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infections, Male Urogenital Diseases, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, Urogenital Diseases, acute kidney injury, kidney disorder, kidney failure, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, urinary system disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Phase 2 / Phase 3 | 2025-03-03 | NCT05815485 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The University of Texas Medical Branch, Galveston | 59 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Rush University | Chicago | United States | 36 |
| University of Michigan | Ann Arbor | United States | 538 |
| University of Texas Medical Branch | Galveston | United States | 45 |